NANOLEK is the first in Russia to produce inactivated polio vaccine.« Назад
On 11th of November, there has been a grand opening of an innovative vaccines and biotechnological production of NANOLEK located in Kirov. The new production is based on the most modern technologies, some of which are pioneer representatives in Russia, and fits high-set international quality standards, which is demonstrated by numerous partnerships with large multinational companies (Sanofi Pasteur, Merck, Celltrion, Egis, Aspen, TEVA etc.) which results in a number of socially important products brought into Russian market.
Since late 2014, the factory has been producing medications in solid dosage forms: products of its own development as well as those within the framework of contract manufacturing. In a biotechnological site of NANOLEK products in vial and parenteral dosage forms will now be manufactured with volumes predicted to reach up to 42 million pre-filled syringes and 35 million vials per year. The area of land around the plant pledges further expansion and an increase in output quantities.
From the foundation day the company has been actively developing a set of vaccines aiming at completing and further growth of the National Vaccination Calendar. The first vaccine to be produced by NANOLEK will be POLIMILEX – an inactivated vaccine for polio prevention, with state registration expected to be completed in the nearest time. The vaccine will become the first inactivated polio vaccine to be manufactured in Russia. In partnership with Bilthoven Biologicals (Netherlands) NANOLEK has been conducting a transferal of the vaccine’s production technology to the biomedical plant from 2012, with vaccine supply for public health services in Russia planned to begin in 2017.
The government is currently passing on a policy targeting the extension of use of the inactivated polio vaccine within the confines of National Food Industry Commission, which totally supports the strategy of the World Health Organization, which aims at a global annihilation of polio and allows to eliminate the chance of getting infected through a vaccine-associated polio completely. As many epidemiologists claim, there are two types of polio vaccines - an inactivated poliovirus vaccine (IPV) and an oral poliovirus vaccine (OPV). Contact with people, vaccinated with the latter may pass on the infection to those, who haven’t undergone vaccination yet. This is the origin of the so-called vaccine-associated polio. To avoid those cases, in 1990s the first two vaccinations were IPVs. This significantly dropped the probability of getting a “handmade” infection and moreover it allowed children who were intolerant to OPV to be vaccinated.
Considering the global deficit of demand for the inactivated polio vaccine, in future, as the production continues to expand, there is a scope for international growth, including UNICEF.